Antilymphocyte serum: a review with report of the current clinical situation in Australia.
D000818:Animals; D000937:Antigen-Antibody Reactions; D000941:Antigens; D000961:Antilymphocyte Serum / Q000008:administration & dosage / Q000009:adverse effects / Q000096:biosynthesis / Q000627:therapeutic use; D001315:Australia; D001798:Blood Proteins; D006168:Guinea Pigs; D000882:Haplorhini; D006648:Histocompatibility; D006736:Horses / Q000276:immunology; D006801:Humans; D007114:Immunization; D007116:Immunization, Passive; D007166:Immunosuppressive Agents / Q000633:toxicity; D016030:Kidney Transplantation; D008214:Lymphocytes / Q000276:immunology; D051379:Mice; D051381:Rats; D013154:Spleen / Q000276:immunology; D013950:Thymus Gland / Q000276:immunology; D014182:Transplantation, Autologous / Q000401:mortality; D005719:gamma-Globulins
D000941:Antigens; D000961:Antilymphocyte Serum; D001798:Blood Proteins; D007166:Immunosuppressive Agents; D005719:gamma-Globulins